Adherence, persistence, concordance: do we provide optimal management to our patients with osteoporosis?

Joint Bone Spine

Volumn 73, Issue 5, 2006, Pages

  Cortet, Bernard ^a   Bénichou, Olivier ^b  

^a Rheumatology Department   (France)

^b Women's Health Department Lilly   (France)

Author keywords

Adherence; Bisphosphonate; Compliance; Hormone replacement therapy; HRT; Osteoporosis; Persistence; Raloxifene

Indexed keywords

ALENDRONIC ACID; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; ANTITHROMBOCYTIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CALCIUM CHANNEL BLOCKING AGENT; CONJUGATED ESTROGEN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ETIDRONIC ACID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; RALOXIFENE; RISEDRONIC ACID; VITAMIN D; BONE DENSITY CONSERVATION AGENT;

ABDOMINAL PAIN; AWARENESS; BONE TURNOVER; CHRONIC DISEASE; CLINICAL PRACTICE; CLINICAL TRIAL; DIABETES MELLITUS; DISEASE SEVERITY; DOCTOR PATIENT RELATION; DRUG COST; DRUG DOSE REGIMEN; FEAR; FRAGILITY FRACTURE; GASTROINTESTINAL SYMPTOM; HEALTH CARE SYSTEM; HORMONE SUBSTITUTION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; INTERVENTION STUDY; LONG TERM CARE; MEDICAL DOCUMENTATION; OSTEOPOROSIS; PATIENT ASSESSMENT; PATIENT CARE; PATIENT COMPLIANCE; PATIENT EDUCATION; PATIENT INFORMATION; POSTMENOPAUSE; PRESCRIPTION; SHORT SURVEY; STATISTICAL SIGNIFICANCE; SYMPTOM; METHODOLOGY; PSYCHOLOGICAL ASPECT; REVIEW; RHEUMATOLOGY; STANDARD;

BONE DENSITY CONSERVATION AGENTS; HUMANS; OSTEOPOROSIS; PATIENT COMPLIANCE; RHEUMATOLOGY;

EID: 33750588037     PISSN: 1297319X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jbspin.2006.02.006     Document Type: Short Survey

References (32)

1. Oleksik A., Lips P., Dawson A., Minshall M.E., Shen W., Cooper C., et al. Health related quality of life in post menopausal women with low BMD with or without prevalent vertebral fractures. J. Bone Miner. Res. 15 (2000) 1384-1392
2. Cauley J.A., Thompson D.E., Ensrud K.C., Scott J.C., and Black D. Risk of mortality following clinical fractures. Osteoporos. Int. 11 (2000) 556-561
3. Hughes C.M. Medication non-adherence in the elderly. How big is the problem?. Drugs Aging 21 (2004) 793-811
4. Mallion J.M., Baguet J.P., and Siche J.P. Compliance, electronic monitoring and antihypertensive drugs. J. Hypertens. 16 Suppl 1 (1997) S75-S80
5. Schroeder K., Fahey T., and Ebrahim S. How can we improve adherence to blood pressure-lowering medication in ambulatory care? Systematic review of randomized controlled trials. Arch. Intern. Med. 164 (2004) 722-732
6. Conlin P.R., Gerth W.C., Fox J., Roehm J.B., and Boccuzzi S.J. Four-year persistence patterns among patients initiating therapy with the angiotensin II receptor antagonist losartan versus other artihypertensive drug classes. Clin. Ther. 23 (2001) 1999-2010
7. Cramer J.A. A systematic review of adherence with medications for diabetes. Diabetes Care 27 (2004) 1218-1224
8. Benner J.S., Glynn R.J., Mogun H., Neumann P.J., Weinstein M.C., and Avorn J. Long-term persistence in use of statin therapy in elderly patients. JAMA 288 (2002) 455-461
9. Jackevicius C.A., and Mamdani Tu J.V. Adherence with statin therapy in elderly patients with and without acute coronary syndromes. JAMA 288 (2002) 462-467
10. Jones J.K., Gorkin L., and Lian J.F. Discontinuation of and changes in treatment after start of new courses of antihypertensive drugs: a study of a United Kingdom population. BMJ 311 (1995) 293-295
11. Owen S.G., Friesen W.T., Roberts M.S., and Flux W. Determinants of compliance in rheumatoid arthritic patients assessed in their home environment. Br. J. Rheumatol. 24 (1985) 313-320
12. Brewer N.T., Chapman G.B., Brownlee S., and Leventhal E.A. Cholesterol control, medication adherence and illness cognition. Br. J. Health Psychol. 7 (2002) 433-447
13. Carney R.M., Freedland K.E., Eisen S.A., Rich M.W., and Jaffe A.S. Major depression and medication adherence in elderly patients with coronary artery disease. Health Psychol. 14 (1995) 88-90
14. Gray S.L., Mahoney J.E., and Blough D.K. Medication adherence in elderly patients receiving home health services following hospital discharge. Ann. Pharmacother. 35 (1987) 539-545
15. Stephenson B.J., Rowe B.H., Haynes R.B., Macharia W.M., and Leon G. The rational clinical examination. Is this patient taking the treatment as prescribed?. JAMA 269 (1993) 2779-2781
16. Urquhart J. Patient compliance with crucial drug regimens: implications for prostate cancer. Eur. Urol. 29 Suppl. 2 (1996) 124-131
17. Park D.C., Morrell R.W., Frieske D., and Kincaid D. Medication adherence behaviours in older adults: effects of external cognitive supports. Psychol. Aging 7 (1992) 252-256
18. Hussey L.C. Overcoming the clinical barriers of low literacy and medication non-compliance among the elderly. J. Gerontol. Nurs. 17 (1991) 27-29
19. Patton K., Meyers J., and Lewis B.E. Enhancement of compliance among patients with hypertension. Am. J. Manag. Care 3 (1997) 1693-1698
20. Zanchetta J.R., Akim C., and Lombas C. Observational study of compliance and continuance rates of raloxifene in the prevention and treatment of osteoporosis. Curr Therapeutic Res 65 (2004) 470-480
21. Recker R.R., Gallagher R., Amonkar M., Smith J.C., and MacCosbe P.E. Medication persistence is better with weekly bisphosphonates but it remains sub-optimal. J. Bone Miner. Res. 19 Suppl 1 (2004) S172
22. Cramer J.A., Amonkar M.M., Hebborn A., and Suppapanya N. Does dosing regimen impact persistence with bisphosphonate therapy among postmenopausal osteoporotic women?. J. Bone Miner. Res. 19 Suppl 1 (2004) S448
23. Boccuzzi S.J., Foltz S.H., Omar M.A., and Kahler K.H. Assessment of adherence and persistence with daily and weekly dosing regimens of oral bisphosphonates. Osteoporos Int. 16 Suppl 3 (2005) S3
24. Segal E., Tamir A., and Ish-Shalom A.S. Compliance of osteoporotic patients with different treatment regimens. Isr. Med. Assoc. J. 5 (2003) 859-862
25. Turbi C., Herrero-Beaumont G., Acebes J.C., Torrijos A., Grana J., Miguelez R., et al. Compliance and satisfaction with raloxifene versus alendronate for the treatment of postmenopausal osteoporosis in clinical practice: an open-label, prospective, nonrandomized, observational study. Clin. Ther. 26 (2004) 245-256
26. Boccuzzi S.J., Foltz S.H., Omar M.A., Kahler K.H., and Guttierez B. Adherence and persistence associated with pharmacology treatment of osteoporosis. Osteoporos. Int. 16 Suppl 3 (2005) S24
27. Caro J.J., Ishak K.J., Huybrechts K.F., Raggio G., and Naujoks C. The impact of compliance with osteoporosis therapy on fracture rates in actual practice. Osteoporos. Int. 15 (2004) 1003-1008
28. Resnik B., Wehren L., and Orwing D. Reliability and validity of the self-efficacy and outcome expectations for osteoporosis medication adherence scales. Orthop. Nurs. 22 (2003) 139-147
29. Unson C.G., Siccion E., Gaztambide J., Gaztambide S., Trella P.M., and Prestwood K. Nonadherence of osteoporosis treatment preferences of older women: a qualitative study. J. Womens Health (Larchmt) 12 (2003) 1037-1045
30. Chapurlat R.D., and Cummings S.R. Does follow-up of osteoporotic women treated with antiresorptive therapies improve effectiveness?. Ostoeoporos. Int. 13 (2002) 738-744
31. Clowes J.A., Peel N.F.A., and Eastell R. The impact of monitoring on adherence and persistence with antiresorptive treatment for postmenopausal osteoporosis: a randomized controlled trial. J. Clin. Endocrinol. Metab. 89 (2004) 1117-1123
32. Delmas P., Vrijens B., Eastell R., Roux C., Lemoigne-Amrani A., Grauer A., et al. Effect of monitoring risedronate treatment of postmenopausal osteoporosis with bone turnover markers: the Impact study. J. Bone Miner. Res. 18 Suppl 2 (2003) S374